Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Pilot Study of MSCs Iufusion and Etanercept to Treat Ankylosing Spondylitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02809781
Recruitment Status : Unknown
Verified June 2016 by Shen Huiyong, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.
Recruitment status was:  Recruiting
First Posted : June 22, 2016
Last Update Posted : June 24, 2016
Sponsor:
Collaborators:
Nanfang Hospital of Southern Medical University
Second Affiliated Hospital of Guangzhou Medical University
Information provided by (Responsible Party):
Shen Huiyong, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Tracking Information
First Submitted Date  ICMJE June 16, 2016
First Posted Date  ICMJE June 22, 2016
Last Update Posted Date June 24, 2016
Study Start Date  ICMJE June 2016
Estimated Primary Completion Date August 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 19, 2016)
The Assessment of Spondyloarthritis International Society (ASAS)20 response [ Time Frame: 48 weeks ]
ASAS measures symptomatic improvement in AS patients.ASAS=4 domains:patient global assessment of disease activity,pain,function,inflammation.ASAS 20=20% improvement(vs.baseline)and an absolute change≥1 units on a 0-10 scale(0=no disease activity;10=high disease activity)for ≥3 domains,and no worsening in remaining domain.
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT02809781 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: June 19, 2016)
  • BASDAI score comparing to baseline [ Time Frame: 48 weeks ]
  • BASFI score comparing to baseline [ Time Frame: 48 weeks ]
    the Bath Ankylosing Spondylitis Functional Index
  • Imageology [ Time Frame: 48 weeks ]
    The bone marrow of the whole spine (from C2 to S1) can be detected by Magnetic resonance imaging (MRI) scan. The MRI sequence included a T1-weighted turbo spin-echo (TSE) sequence and a fat-saturated short tau inversion recovery (STIR) sequence. MR images were first analyzed using the ASspiMRI-a scoring system , which is based on grading disease activity on a scale of 0 to 6. In addition to the ASspiMRI-a scoring system, the inflammation area and average intensityof each inflammatory site were calculated. The background value (BV) was obtained by taking 10 normal sites of the vertebral body of 1 layer and calculating the average. The inflammation extent of each inflammatory site was calculated by the formula: value of inflammation area (VIA) × [value of average intensity (VAI) - BV]. The summation of the inflammation extent of all inflammatory sites in all scanning layers was defined as the total inflammation extent (TIE) of each patient.
  • C-reactive protein (CRP) [ Time Frame: 12 weeks ]
  • Erythrocyte sedimentation rate (ESR) [ Time Frame: 12 weeks ]
  • Tumor necrosis factor alpha (TNF-α) [ Time Frame: 12 weeks ]
  • Interleukin 6 (IL-6) [ Time Frame: 12 weeks ]
  • Interleukin 17 (IL-17) [ Time Frame: 12 weeks ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures
 (submitted: June 19, 2016)
  • Percentage of systemic T cell population [ Time Frame: 12 weeks ]
  • Side effects [ Time Frame: 48 weeks ]
    These parameters monitored throughout the trial included body temperature, pulse rate, respiration rate, blood pressure, complete blood count (CBC), routine urine and stool testing, blood creatinine, alanine transaminase, and aspartate transaminase levels, anti-nuclear antibody testing, electrocardiogram, and chest radiographs. These data were obtained by skilled allied health professionals strictly according to the international standardized procedure when patients were enrolled in this study.
Original Other Pre-specified Outcome Measures Same as current
 
Descriptive Information
Brief Title  ICMJE A Pilot Study of MSCs Iufusion and Etanercept to Treat Ankylosing Spondylitis
Official Title  ICMJE Phase III Study of Human Bone Marrow-Derived Mesenchymal Stem Cells to Treat AS
Brief Summary The purpose of this study is to evaluate the safety and clinical effect of mesenchymal stem cells (MSCs) derived from human bone marrow at a dose of 1.0E+6 MSC/kg in subject for the therapy of Ankylosing spondylitis (AS) and to compare the efficacy of MSCs and Etanercept to treat this disease.
Detailed Description

Ankylosing spondylitis (AS) is a chronic, progressive inflammatory rheumatic disease involving primarily the sacroiliac joints and the axial skeleton. The main clinical features are back pain and progressive stiffness of the spine. Oligoarthritis of the hips and shoulders, enthesopathy, and anterior uveitis are common, and involvement of the heart and lungs is rare. The current understanding of the pathogenesis of this disorder is limited.It mainly about to hereditary susceptibility (eg HLA-B27),infection and autoimmunity.

Although traditional drugs, such as Nonsteroidal antiinflammatory drugs (NSAIDs) disease-modifying antirheumatic drugs (DMARDs such as methotrexate, salicylazosulfapyridine OR thalidomide) and steroids have been used in the treatment of AS, however, many studies have indicated that the overall response to these drugs is not satisfied. Addition, the severe side effects of these drugs have also been observed. The management of AS patients therefore remains unsatisfactory and targeted therapies are needed. Although the application of TNF alpha receptor inhibitor (such as Etanercept) has got the success in the early treatment of ankylosing spondylitis, the tolerance to this biological agent make the therapy to this disease rather difficult. Recently, owning to its immunoregulatory, immunosuppressive, stimulating hematopoiesis and tissue repairing properties, the infusion of human MSCs isolated from human bone marrow have been a promising and effective treatment to AS patients. This study will evaluate the safety and effectiveness of MSC transplantation in the AS patients and compare the efficiency with the Etanercept to treat AS patients.

This study will last 2 to 3 years. Participants will be randomly assigned to receive either MSC transplant therapy (experimental group) or Etanercept therapy (control group). Patients will undergo MSC transplant at the start of the study on Day 0. The experimental group will receive infusion per week in the first 4 weeks and every two weeks in the second 8 weeks, totally for 12 weeks. After 3 months, patients will receive the second MSC transplantation. After 12 weeks (Phase I) and 48 weeks (Phase II) from the first transplantation, patients will be evaluated.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Spondylitis
  • Spondylitis, Ankylosing
  • Ankylosis
  • Arthritis
  • Spondylarthritis
  • Spondylarthropathies
  • Spinal Diseases
  • Musculoskeletal Diseases
  • Bone Diseases
Intervention  ICMJE
  • Biological: Intravenous infusion of MSCs
    Intravenous infusion of MSCs:Human bone marrow-derived MSCs 1.0E+6 MSC/kg, IV drop
  • Drug: Etanercept
    50mg,hypodermic injection,once per week, for 12 weeks
    Other Name: TNF alpha receptor inhibitor
Study Arms  ICMJE
  • Experimental: Intravenous infusion of MSCs
    Human bone marrow-derived MSCs at a dose of 1.0E+6 MSC/kg, receive infusion per week in the first 4 weeks and every two weeks in the second 8 weeks. total for 12 weeks.
    Intervention: Biological: Intravenous infusion of MSCs
  • Active Comparator: Etanercept
    50mg,hypodermic injection,once per week, for 12 weeks
    Intervention: Drug: Etanercept
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Unknown status
Estimated Enrollment  ICMJE
 (submitted: June 19, 2016)
250
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 2018
Estimated Primary Completion Date August 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. The male or female patient aged 18 to 45 years;
  2. Fulfill 1984 modified NewYork classification criteria for AS;
  3. The score of the Bath AS Disease Activity Index (BASDAI)≥40 on (0-100) despite optimal non-steroidal anti-inflammatory drug (NSAID) treatment.
  4. Before each experiment, patients subscribe voluntarily to the agreement approved by Ethics Committees and sign the date.

Exclusion Criteria:

  1. The patient diagnosed in doubt;
  2. Completely stiff spine
  3. Received spinal or joint surgery within 2 months
  4. Received anti-TNF therapy within 3 months
  5. pregnant or suckling period female patients;
  6. Patients with the Medical or mentally imbalance charged by researchers. patients associated cardiovascular, cerebrovascular, liver,renal and hematological system diseases or mental disease;
  7. Patients could not accept the research or could not cooperate well. Patients with other sever diseases at the same time, such as abnormality of joints, other seronegative spondyloarthropathy, or other Rheumatic Diseases.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 45 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE China
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02809781
Other Study ID Numbers  ICMJE SYSU-81332612
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Plan Description: It all depends on the whole process of the study.
Responsible Party Shen Huiyong, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study Sponsor  ICMJE Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Collaborators  ICMJE
  • Nanfang Hospital of Southern Medical University
  • Second Affiliated Hospital of Guangzhou Medical University
Investigators  ICMJE
Principal Investigator: Shen Huiyong, Doctor Sun Yat-sen Memorial Hospital,Sun Yat-sen University
PRS Account Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Verification Date June 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP